iwCLL

1-888-476-9129 info@bioascend.com

Menu
2017 Presentations

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients With CLL With Mutated IGHV


Nitin Jain